Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

NCT01753323 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Malaria

Interventions

DRUG: KAF156

Sponsor

Novartis Pharmaceuticals